The wrong track: How papillomaviruses trick the immune system

August 04, 2020

Specific antibodies protect us against viral infections - or do they not? Researchers at the German Cancer Research Center (DKFZ) studied the immune response to papillomaviruses in mice and discovered a hitherto unknown mechanism by which the pathogens outwit the immune system: At the beginning of the infection cycle, they produce a longer version of a protein that surrounds the viral genome. The body produces antibodies against this protein, but they are not effective in fighting the pathogen.

The human immune system has a wide variety of defense strategies to protect the body against pathogens, one of which involves producing antibodies to fight viruses and bacteria. Over time, however, these pathogens have developed elaborate ways of escaping the immune system.

Scientists are already aware of some of these strategies. In human papillomaviruses (HPV), however, up until now they have only known about such strategies in innate, already present immunity and not in adaptive immunity, which does not develop until pathogens enter the body and is associated with the production of antibodies.

Frank Rösl and his co-workers from DKFZ under the supervision of Daniel Hasche have now discovered a new mechanism by which cutaneous papillomaviruses (specific to the skin) trick the immune system.

Certain cutaneous HPV, such as HPV5 and HPV8, occur as natural infections on the skin. They are not sexually transmitted, but are passed on from the mother to the newborn child. Thus, family members are usually colonized with the same HPV types. An infection normally goes unnoticed, because the body is able to overcome it. Depending on the individual status of a person's immune system, their genetic predisposition, age, and other external factors such as UV radiation, however, certain cutaneous HPV types are able to stimulate cell division in their host cells. This leads to skin changes and in rare cases to development of a squamous cell carcinoma, also known as fair-skin cancer.

The experiments were conducted in a particular mouse species, Mastomys coucha, which, like humans, can become infected with cutaneous papillomaviruses shortly after birth and produce specific antibodies against the virus. In combination with UV radiation, infected animals are more likely to develop squamous cell cancer.

The animals' immune system produces antibodies against the two viral proteins L1 and L2 that make up the virus particles, also called capsids. These antibodies can prevent the viruses from entering the host cells and thus neutralize the virus. However, the experiments carried out by the DKFZ scientists showed that besides the normal L1 protein, the viruses also produce a longer version. The latter is not able to actually take part in forming the viral capsid. Instead, it acts as a kind of bait against which the immune system directs its response and produces specific antibodies.

However, the scientists were able to demonstrate that these antibodies are not effective in fighting the papillomavirus. Instead of neutralizing the infectious pathogen through binding to L1, the antibodies merely bind the nonfunctional protein used as bait. While the immune system is busy producing these non-neutralizing antibodies, the virus can continue to replicate and spread throughout the body. It take several more months before neutralizing antibodies are produced that target the normal L1 protein and ultimately the infectious viruses themselves.

"In both rodents and humans, in almost all HPV types that can cause cancer, the L1 gene is designed such that a longer version of the protein can be produced. This is also true for high-risk HPV types such as HPV16 and HPV18, which can cause cervical cancer. It therefore appears to be a common mechanism that enables the viruses to replicate and spread efficiently during the early stage of infection", Daniel Hasche explained. "The fact that antibodies against papillomaviruses can be detected is therefore not necessarily associated with protection against infection. This will need to be taken into account in future when evaluating and interpreting epidemiological studies," Frank Rösl added.
-end-
The present study was funded by the Wilhelm Sander Foundation (2018.093.1 and 2010.019.1), the German Federal Ministry of Education and Research (BMBF, 031L0095B), and the China Scholarship Council (CSC).

Yingying Fu, Rui Cao, Miriam Schäfer, Sonja Stephan, Ilona-Braspenning-Wesch, Laura Schmitt, Ralf Bischoff, Martin Müller, Kai Schäfer, Sabrina E. Vinzón, Frank Rösl and Daniel Hasche: Expression of different L1 isoforms of Mastomys natalensis papillomavirus as amechanism to circumvent adaptive immunity. eLife 2020, https://doi.org/10.7554/eLife.57626

A photo is available for download:

http://www.dkfz.de/de/presse/pressemitteilungen/2020/bilder/Striking-Image.jpg

Picture caption: Papillomaviruses in the stratum corneum of a skin tumor of a Mastomys coucha

Note on use of images related to press releases

Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: Michelle Neßling/DKFZ".

Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.